This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. R. MARGULIS, M.D.; B. E. BRUSH, M.D.

AMA Arch Surg. 1952;65(4):511-521.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

WE ARE presenting our experience with the enzymatic agent fibrinolysin in the treatment of several surgical complications. One hundred instances in which the material was used are reviewed in order to evaluate its worth. The proenzyme, profibrinolysin, occurs naturally and circulates in human and animal plasma. The proenzyme becomes activated under certain circumstances during life and also post mortem. It has been shown that an extract of a Streptococcus culture, Lancefield A., possesses an enzyme activator which changes profibrinolysin to active fibrinolysin. This activator is streptokinase, which has itself been used in enzymatic débridement.¹ Epinephrine and chloroform also have the ability to activate profibrinolysin.

As early as 1893 a Frenchman, Dastre,² called attention to the proteolytic activity of the blood serum. Fibrinolysin was first isolated in almost pure form in 1946 by E. C. Loomis and his associates.^1a The material used in this study was obtained from . . . [Full Text PDF of this Article]

Author Affiliations
DETROIT

From the Department of Surgery and Gynecology, Henry Ford Hospital.

Footnotes
Read at the Ninth Annual Meeting of the Central Surgical Association, Toronto, Canada, March 7, 1952.

Fibrinolysin was obtained through the courtesy of Parke, Davis & Company, Department of Clinical Investigation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?